Earnings ·
Ardelyx reports Q3 product revenue of $125.5 million, up 19% year-over-year
ARDXArdelyx, Inc.
Ardelyx reported third-quarter 2026 total product revenue of $125.5 million, a 19% increase from the prior-year period. IBSRELA sales grew 23% to $96.3 million, while XPHOZAH revenue rose 7% to $29.2 million. The company reported a net loss of $0.7 million for the quarter and reaffirmed its full-year 2026 guidance, projecting IBSRELA revenue between $350 million and $370 million and XPHOZAH revenue between $110 million and $120 million. Ardelyx also announced that enrollment in its Phase 3 ACCEL trial for chronic idiopathic constipation was completed ahead of schedule, with topline data expected in the second half of 2027. The company operates as a commercial-stage biopharmaceutical firm focused on developing and commercializing innovative medicines for unmet medical needs.